As previously stated, GLP-1R agonists stimulate cardiac glucose metabolism [107], and GLP-1 infusion for 3 months also improves survival and LVEF, while decreasing cardiac hypertrophy in spontaneously hypertensive, heart failure-prone obese rats, though glucose oxidation rates were not assessed in this study [120]. The gene discussed is GLP1R; the disease is heart failure.